###begin article-title 0
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Novel mutations of CHST6 in Iranian patients with macular corneal dystrophy
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
To characterize mutations within the carbohydrate sulfotransferase 6 (CHST6) gene in Iranian subjects from 12 families with macular corneal dystrophy (MCD).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Genomic DNA was extracted from peripheral blood of 20 affected patients and 60 healthy volunteers followed by polymerase chain reaction (PCR) and direct sequencing of the CHST6 coding region. The observed nucleotide sequences were then compared with those found by investigators in other populations with MCD and in the controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
Analysis of CHST6 revealed 11 different mutations. These mutations were comprised of six novel missense mutations (p.F55L, p.P132L, p.S136G, p.C149Y, p.D203Y, and p.H249R), one novel nonsense mutation (p.S48X), one novel frame shift (after P297), and three previously reported missense mutations (p.P31L, p.C165Y, and p.R127C). The majority of the detected MCD mutations are located in the binding sites or the binding pocket, except the p.P31L and p.H249R mutations.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
Nucleotide changes within the coding region of CHST6 are predicted to significantly alter the encoded sulfotransferase within the evolutionary conserved sequences. Our findings show that CHST6 mutations are responsible for the pathogenesis of MCD in Iranian patients. Moreover, the observation that some cases of MCD cannot be explained by mutations in the coding region of CHST6 suggests that MCD may result from possible upstream rearrangements in the CHST6 genomic region.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 858 859 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
###xml 971 978 <span type="species:ncbi:9606">patient</span>
Corneal dystrophies are a heterogeneous group of disorders that may lead to severe visual impairment of which macular corneal dystrophy (MCD; OMIM ) is transmitted as an autosomal recessive trait [1]. The prevalence of MCD varies immensely in different parts of the world, but in most populations, the condition is rare. As a treatment, penetrating keratoplasty is performed when useful vision has been lost. Reportedly, in Iceland and Japan, MCD accounts for 75% and 10%, respectively, of the corneal dystrophies requiring corneal grafting [2,3]. Clinical symptoms usually manifest within the first decade of life, and MCD patients show spotted opacity in both corneas. These abnormal deposits are associated with a central stromal haze that gradually extends to the periphery of the cornea, leading to visual impairment, and patients require keratoplasty [4]. MCD has been subdivided into three immunophenotypes (MCD types I, IA, and II) based on the reactivity of the patient's serum and corneal tissue to monoclonal anti-keratan sulfate antibody (5D4 anti-KS antibody) [5].
###end p 11
###begin p 12
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 352 353 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 418 419 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 898 899 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 900 901 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
Biochemical studies have indicated that a specific sulfation step of keratan sulfate is impaired in MCD, resulting in an accumulation of glycosaminoglycans (GAGs). Keratan sulfate proteoglycan, the most abundant carbohydrate in the cornea, plays an important role in maintenance of corneal transparency [6,7]. Keratan sulfate consists of a linear poly-N-acetyllactosamine chain that carries sulfate residues on C-6 of N-acetylglucosamine (GlcNAc) and galactose (Gal). Because the sulfation of carbohydrates affects their biochemical characteristics such as water solubility and electrical charge, this modification appears to be important for the function of keratan sulfate proteoglycans in the cornea. Considering the importance of the sulfated carbohydrates of keratan sulfate in the normal function of the cornea, it has been suggested that lack of this sulfation step is a major cause of MCD [6,8,9].
###end p 12
###begin p 13
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
It has also recently been shown that there is a failure in the activity of corneal GlcNAc 6-O-sulfotransferase (C-GlcNAc6ST), which transfers sulfate to position 6 of GlcNAc residues and this enzyme participates in biosynthesis of corneal keratan sulfate proteoglycan. In the cornea of patients with MCD, a decrease in C-GlcNAc6ST activity results in the formation of poorly sulfated or non-sulfated keratan sulfate and causes corneal opacity [10,11].
###end p 13
###begin p 14
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
Using genetic linkage analysis, the critical region for MCD has been mapped to chromosome 16 (16q22). The carbohydrate sulfotransferase 6 gene (CHST6) was identified within the MCD critical region encoded C-GlcNAc6ST, and mutations in CHST6 have been shown to be the fundamental defect in MCD [12,13].
###end p 14
###begin p 15
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
In the present study, which is the first comprehensive work studying Iranian subjects with MCD, we screened 20 patients with MCD from 12 families to search for mutations in CHST6. We identified seven novel mutations and four previously reported disease-causing mutations.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
This study was performed in accordance with the Declaration of Helsinki and with the approval of the ethics board of the Amiralmomenin Hospital and Guilan University (Rasht, Iran). Twenty patients from 12 unrelated Iranian families who received clinical diagnosis of MCD were included in this study. Diagnosis for MCD in affected individuals was made by cornea specialists at the Amiralmomenin Hospital (associated with Guilan University of Medical Sciences). All patients were older than 25 years, and the obtained pedigrees were consistent with an autosomal recessive inheritance pattern. There was not any known consanguinity in the patients' families. Sixty unrelated, unaffected, and healthy volunteers were recruited to serve as controls.
###end p 18
###begin p 19
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from a peripheral blood vessel from affected patients and healthy volunteers. Genomic DNA was extracted by standard procedure using the PAX gene blood DNA kit (Qiagen, Valencia, CA).
###end p 19
###begin title 20
DNA analysis
###end title 20
###begin p 21
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
The coding region of CHST6 was amplified using polymerase chain reaction (PCR) and the primers designed to create three overlapping amplicons. The oligonucleotide primers used were identical to those reported by Akama and associates [12].
###end p 21
###begin p 22
###xml 139 140 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Each reaction was performed in a 50-microl volume comprising of genomic DNA (100 ng), 10X PCR buffer, 0.2 microM dNTP, 1.5-2 microM of MgCl2, 0.2 microM of each primer, 1 U of Taq DNA polymerase (Qiagen). The thermal cycling was performed using the following protocol 2 min at 96 degreesC and 35 cycles of 30 s at 96 degreesC, 30 s at 57 degreesC, 45 s at 72 degreesC, and final extension 7 min at 72 degreesC followed by a 4 degreesC hold cycle.
###end p 22
###begin p 23
###xml 369 374 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 375 380 <span type="species:ncbi:9606">human</span>
The PCR products were then purified using the QIAquick PCR purification kit (Qiagen) and sequenced on both strands by the ABI BigDye terminator chemistry and an ABI Prism 3700 instrument (Applied Biosystems, Foster City, CA). Sequences were analyzed using the Sequencher software (Gene Codes Corporation, Ann Arbor, MI) and compared with the nucleotide sequence of the CHST6 human cDNA (GenBank accession number ).
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 226 233 226 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
A total of 20 affected patients representing 12 different families were enrolled in the study. The most abnormalities found in this study were single base changes in the coding region of CHST6 that altered a coded amino acid (Table 1), seven of which were homozygous. The nucleotide changes included c.92C>T, c.143C>A, c.165C>A, c.379C>T, c.406A>G, and c.746A>G, resulting in a proline to a leucine substitution (p.P31L), a serine to stop codon substitution (p.S48X), a phenylalanine to a leucine substitution (p.F55L), an arginine to a cysteine substitution (p.R127C), a serine to a glycine (p.S136G), and a histidine to an arginine substitution (p.H249R).
###end p 25
###begin title 26
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
CHST6 mutations in Iranian patients with MCD.
###end title 26
###begin p 27
In the table "+" denotes that the observed changes are Disease-causing, and "-" denotes that the observed changes are not Disease-causing.
###end p 27
###begin p 28
In family C, an insertion of a single base pair between nucleotides 891 and 892 was identified, resulting in a frame shift after codon, P297 (p.P297fs).
###end p 28
###begin p 29
In addition, a compound heterozygosity was detected in family E. In this family, a heterozygous changes, c.395C>T and c.494G>A, was identified, predicting amino acid changes of proline to leucine (p.P132L) and cysteine to tyrosine (p.C165Y).
###end p 29
###begin p 30
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
In two families, only one heterozygous pathogenic change was observed in the coding CHST6 sequence. In family F, we found c.446G>A, which replaces a cysteine to a tyrosine (p.C149Y). In family H, c.607G>T was found, replacing an aspartic acid to a tyrosine (p.D203Y).  In the last two families (K and L), no presumable pathogenic change was detected. In addition, a single novel nucleotide polymorphism, c.405C>T (a heterozygous change), was found in family K. It was considered a non-pathogenic sequence variant because it had no effect on the amino acid.
###end p 30
###begin p 31
###xml 165 173 <span type="species:ncbi:9606">patients</span>
The amplified PCR products from 60 control individuals were analyzed for each alteration using direct sequencing, none of which indicated the mutations seen for the patients.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
In this study, we examined the CHST6 coding region for mutations in 20 individuals with MCD from 12 Iranian families. Sequencing analysis revealed six novel missense mutations (p.F55L, p.P132L, p.S136G, p.C149Y, p.D203Y, and p.H249R), one nonsense mutation (p.S48X), one frame shift (p.P297fs), and three previously reported missense mutations (p.P31L [13], p.C165Y [14], and p.R127C [15]) in CHST6 in the Iranian patients with MCD.
###end p 33
###begin p 34
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 240 241 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 565 566 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 640 648 640 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
CHST6 encodes the C-GlcNAc6ST, comprising 395 amino acids. This enzyme is localized in the Golgi apparatus and is a member of the Gal/GalNAc/GlcNAc 6-O sulfotransferase (GST) family. The C-GlcNAc6ST contains a short cytosolic tail at the NH2-terminal, a single transmembrane span, and a COOH-terminal domain that contains two putative binding sites for the high energy sulfate donor (adenosine3'-phosphate-5'phosphosulfonate [PAPS]). One of the binding sites is the 5'-phosphosulfate binding site (5'-PSB), corresponding to amino acid 49-56, and the other is the RX7S 3'-phosphate binding site (3'-PB), corresponding to amino acid 202-210 (Figure 1). The sequence between the two binding sites is thought to contribute to a binding pocket that interacts with an acceptor (GlcNAc) to bring it into apposition with the sulfate donor [16].
###end p 34
###begin p 35
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Amino acid sequence of C-GlcNAc6ST. This diagram shows the location of missense mutations in Iranian patients with MCD. These mutations are marked by amino acid position using letters with blue arrowheads. Bold letters show the location of the 5'phosphosulfate binding site (5'-PSB) and the 3' phosphate binding site (3'-PB).
###end p 35
###begin p 36
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
It is reported that mutations of these binding motif sequences abolish the sulfotransferase activity in the case of other glycosaminoglycan sulfotransferases, indicating important catalytic roles of these amino acid residues [17].
###end p 36
###begin p 37
###xml 249 250 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
The identified mutation of p.F55L is located in the 5'-PSB domain. The mutations of p.R127C, p.P132L, p.S136G, p.C149Y, p.C165Y are located in the sequence between the 5'-PSB domain, and the 3'-PB domain. The mutation of p.D203Y is located in the RX7S sequence for the 3'-PB domain. Whereas the mutations of p.P31L, p.H249R are neither located in the binding motifs nor in the binding pocket.
###end p 37
###begin p 38
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 1417 1419 1417 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 1420 1422 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1587 1589 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
Amino acid changes at positions 203 and 249 have been previously reported by Akama et al. [12] and Warren et al. [18], respectively, but they are different from the mutations identified in the present study. We have observed c.607G>T causing a replacement of an aspartic acid to a tyrosine (p.D203Y) while in Japanese patients with MCD, a change at nucleotide position 609 (c.609C>A) causes the replacement of an aspartic acid to a glutamic acid at the same protein position (p.D203E) [12]. In Iranian subjects, a change at nucleotide position 746 (c.746A>T) leads to the replacement of a histidine to an arginine at position 249 of the protein (p.H249R) while in Indian patients with MCD, Warren et al. [18] reported c.746A>C resulting in the replacement of a histidine to a cysteine (p.H249C). The identified nonsense coding region mutation would clearly have a significant impact on the encoded enzyme. The nonsense mutation (p.S48X) would result in a premature termination of the encoded protein. Likewise, the insertion of one nucleotide (c.891-892insC) will cause a reading frame shift. It is noteworthy that the occurrence of frame shift and nonsense mutations may lead to the elimination of the protein due to nonsense-mediated decay of the mRNA (NMD). NMD in mammalian cells generally degrades mRNAs that terminate translation more than 50-55 nucleotides upstream of a splicing-generated exon-exon junction [19,20]. NMD downregulates spliced mRNAs that prematurely terminate translation so production of the potentially toxic truncated proteins that they encode does not occur [21].
###end p 38
###begin p 39
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 39 46 <span type="species:ncbi:9606">patient</span>
It is notable that previously only one patient of Iranian origin with MCD was studied. Deletion of the whole open reading frame was identified as the cause in this individual [22]. Additional evidence to support our findings that the sequence changes identified are responsible for producing inactivation of the CHST6 gene product is provided by the fact that no mutations were detected in the CHST6 coding region from control individuals.
###end p 39
###begin p 40
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBI</italic>
###xml 702 708 702 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6 </italic>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
In one family (family L), there were no coding region mutations, and in another family (family K), the nucleotide change had no effect on protein phenotype. These cases of MCD can not be explained by mutations in the coding sequence of CHST6, suggesting that MCD may result from possible upstream rearrangements such as the promotor, which is also part of CHST6 and has not been analyzed in the present study. It is intriguing that such a large number and wide variety of novel mutations were discovered throughout the CHST6 coding sequence. This suggests that in contrast to TGFBI (transforming growth factor, beta induced) with its hot spots for corneal dystrophy-associated amino acid substitution, CHST6 does not demonstrate a highly conserved number of disease-causing mutations [23].
###end p 40
###begin p 41
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
In summary, we identified seven novel and three previously reported CHST6 mutations in our panel consisting of 20 Iranian MCD patients from 12 families. Further analysis of these mutations may help to achieve a clearer understanding of the molecular events leading to the characteristic lesions of MCD.
###end p 41
###begin title 42
Acknowledgments
###end title 42
###begin p 43
We would like to thank the Iranian families for consenting to participate in this study. We would also like to thank Miss Zahra Shaygan for valuable assistance and Dr. Ghader Bashiri for a critical reading of the manuscript.
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
Research into the pathogenesis of macular corneal dystrophy.
###end article-title 45
###begin article-title 46
Macular corneal dystrophy in Iceland.
###end article-title 46
###begin article-title 47
Clinical and histopathologic features of corneal dystrophies in Japan.
###end article-title 47
###begin article-title 48
Linkage of a gene for macular corneal dystrophy to chromosome 16.
###end article-title 48
###begin article-title 49
Immunohistochemical evidence of heterogeneity in macular corneal dystrophy.
###end article-title 49
###begin article-title 50
Macular corneal dystrophy: failure to synthesize a mature keratan sulfate proteoglycan.
###end article-title 50
###begin article-title 51
Physical and biological properties of keratan sulphate proteoglycan.
###end article-title 51
###begin article-title 52
Defective processing of keratan sulfate in macular corneal dystrophy.
###end article-title 52
###begin article-title 53
Macular corneal dystrophy. Lack of keratan sulfate in serum and cornea.
###end article-title 53
###begin article-title 54
Decreased GlcNac 6-O-sulfotransferase activity in the cornea with macular corneal dystrophy.
###end article-title 54
###begin article-title 55
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Human corneal GlcNAc 6-O-sulfotransferase and mouse intestinal GlcNAc6-O-sulfotranseferase both produce keratan sulfate.
###end article-title 55
###begin article-title 56
Macular corneal dystrophy type I and type II are caused by distinct mutations in a new sulfotransferase gene.
###end article-title 56
###begin article-title 57
CHST6 mutations in North American subjects with macular corneal dystrophy: a comprehensive molecular genetic review.
###end article-title 57
###begin article-title 58
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Sequencing of the CHST6 gene in Czech macular corneal dystrophy patients supports the evidence of a founder mutation.
###end article-title 58
###begin article-title 59
Conserved structural motifs in the sulfotransferase family.
###end article-title 59
###begin article-title 60
Structure and function of HNK-1 sulfotransferase: identification of donor and acceptor binding sites by site directed mutagenesis.
###end article-title 60
###begin article-title 61
Novel mutations in the CHST6 gene associated with macular corneal dystrophy in southern India.
###end article-title 61
###begin article-title 62
Nonsense-mediated mRNAdecay: splicing, translation and mRNP dynamics.
###end article-title 62
###begin article-title 63
A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance.
###end article-title 63
###begin article-title 64
Nonsense-mediated mRNA decay in mammals.
###end article-title 64
###begin article-title 65
Differential immunogold localisation of sulphated and unsulphated keratan sulphate proteoglycans in normal and macular dystrophy cornea using sulphation motif-speciWc antibodies.
###end article-title 65
###begin article-title 66
BIGH3 mutation spectrum in corneal dystrophies.
###end article-title 66

